Current Cancer Drug Targets
Volume 22, 11 Issues, 2022
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
ISSN: 1873-5576 (Online)
ISSN: 1568-0096 (Print)
This journal supports open access
Contents
Current Cancer Drug Targets , Volume 12 - Number 7
Editorial
Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium
, 12(7): 743 - 756Fortunato Morabito, Anna Grazia Recchia, Carla Mazzone and Massimo Gentile
DOI: 10.2174/156800912802429373
Molecular Targets for the Treatment of Multiple Myeloma
, 12(7): 757 - 767Marco Rossi, Maria Teresa Di Martino, Eugenio Morelli, Marzia Leotta, Antonietta Rizzo, Anna Grimaldi, Gabriella Misso, Pierfrancesco Tassone and Michele Caraglia
DOI: 10.2174/156800912802429300
Antiangiogenic Therapeutic Approaches in Multiple Myeloma
, 12(7): 768 - 775Domenico Ribatti, Giuseppe Mangialardi and Angelo Vacca
DOI: 10.2174/156800912802429346
Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
, 12(7): 776 - 796Paola Neri and Nizar J. Bahlis
DOI: 10.2174/156800912802429337
Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
, 12(7): 814 - 822P. Tassone, P. Neri, R. Burger, M. T. Di Martino, E. Leone, N. Amodio, M. Caraglia and P. Tagliaferri
DOI: 10.2174/156800912802429292
MicroRNAs in the Pathobiology of Multiple Myeloma
, 12(7): 823 - 837Marta Lionetti, Luca Agnelli, Luigia Lombardi, Pierfrancesco Tassone and Antonino Neri
DOI: 10.2174/156800912802429274
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
, 12(7): 838 - 846P. Tagliaferri, M. Rossi, M. T. Di Martino, N. Amodio, E. Leone, A. Gulla, A. Neri and P. Tassone
DOI: 10.2174/156800912802429355
Anti-Tumor Effect of AlkB Homolog 3 Knockdown in Hormone- Independent Prostate Cancer Cells
, 12(7): 847 - 856K. Koike, Y. Ueda, H. Hase, K. Kitae, Y. Fusamae, S. Masai, T. Inagaki, Y. Saigo, S. Hirasawa, K. Nakajima, I. Ohshio, Y. Makino, N. Konishi, H. Yamamoto and K. Tsujikawa
DOI: 10.2174/156800912802429283
A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
, 12(7): 857 - 872Z. Mihaly, Z. Sztupinszki, P. Surowiak and B. Gyorffy
DOI: 10.2174/156800912802429265
A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis
, 12(7): 873 - 898T. Joyce, E. Oikonomou, V. Kosmidou, E. Makrodouli, I. Bantounas, S. Avlonitis, G. Zografos and A. Pintzas
DOI: 10.2174/156800912802429364
Editor-in-Chief
Ruiwen Zhang
Center for Drug Discovery
University of Houston
Houston, TX
(USA)
Biography
Center for Drug Discovery
University of Houston
Houston, TX
Biography
Biography of Ruiwen Zhang
Ruiwen Zhang is the Robert L. Boblitt Endowed Professor in Drug Discovery and Director of the Drug Discovery Institute at the University of Houston. With over 30 years of experience in the field of biomedical research, particularly in the area of clinical pharmacology and therapeutics, pharmaceutical and toxicological research, Dr. Zhang’s research has been continuously funded by NIH and DoD, and other agencies. He has published more than 230 papers, 2 books, and more than 50 invited reviews/book chapters as well as more than 180 meeting abstracts. For his outstanding contributions in pharmaceutical sciences, Dr. Zhang was elected as a Fellow of American Association for the Advancement of Science (AAAS) in 2009. Dr. Zhang is recently elected as Fellow of National Academy of Inventors (2018).
COPE Compliant
About the Journal
⇨ Journal Home⇨ Editorial Policies⇨ Fabricating and Stating False Information⇨ Research Misconduct⇨ Post Publication Discussions and Corrections⇨ Allegations from Whistleblowers⇨ Editorial Board⇨ Meet the Executive Guest Editor(s)⇨ Board Recruitment Workflow⇨ Short Guide⇨ Join Editorial Board⇨ Indexing Information⇨ Announcements⇨ Endorsements⇨ Authors' Comments
For Authors
For Librarians & Readers
Quick Links
Advertisement
Webmaster Contact: info@benthamscience.net